Ironwood Pharmaceuticals Inc. (IRWD)

18.26
0.33 1.78
NASDAQ : Health Technology
Prev Close 18.59
Open 18.63
Day Low/High 18.08 / 18.63
52 Wk Low/High 12.89 / 21.20
Volume 638.91K
Avg Volume 1.13M
Exchange NASDAQ
Shares Outstanding 139.18M
Market Cap 2.89B
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)
Ironwood Pharmaceuticals Provides Third Quarter 2015 Investor Update

Ironwood Pharmaceuticals Provides Third Quarter 2015 Investor Update

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today provided an update on its third quarter 2015 and recent business activities.

Ironwood Pharmaceuticals Initiates Clinical Studies Of Soluble Guanylate Cyclase Stimulators IW-1973 And IW-1701

Ironwood Pharmaceuticals Initiates Clinical Studies Of Soluble Guanylate Cyclase Stimulators IW-1973 And IW-1701

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the initiation of a Phase Ib clinical study of IW-1973 and a Phase Ia clinical study of IW-1701, both of which are investigational soluble guanylate cyclase...

Ironwood And Allergan Initiate Phase IIb Clinical Trial Of Linaclotide Colonic Release In Adults With Irritable Bowel Syndrome With Constipation

Ironwood And Allergan Initiate Phase IIb Clinical Trial Of Linaclotide Colonic Release In Adults With Irritable Bowel Syndrome With Constipation

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today the initiation of a Phase IIb clinical trial evaluating two orally-administered colonic release formulations of...

'Mad Money' Lightning Round: I'm Not Tempted by Vonage, I Want Verizon

'Mad Money' Lightning Round: I'm Not Tempted by Vonage, I Want Verizon

Cramer says keep Sierra Wireless, avoid Rackspace Hosting and take Weight Watchers gain and go.

Jim Cramer's 'Mad Money' Recap: Using What Went Wrong to Find Buying Opportunities

Jim Cramer's 'Mad Money' Recap: Using What Went Wrong to Find Buying Opportunities

One company's awful earnings can drag others down in the sector, making bargains for the taking, Cramer syas.

First Week of December 18th Options Trading For Ironwood Pharmaceuticals (IRWD)

First Week of December 18th Options Trading For Ironwood Pharmaceuticals (IRWD)

Investors in Ironwood Pharmaceuticals Inc. saw new options become available this week, for the December 18th expiration.

Ironwood Highlights Refractory GERD And Constipation Research At The American College Of Gastroenterology 2015 Annual Scientific Meeting

Ironwood Highlights Refractory GERD And Constipation Research At The American College Of Gastroenterology 2015 Annual Scientific Meeting

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced a series of oral and poster presentations at the American College of Gastroenterology 2015 Scientific Meeting in Honolulu, HI, October 16 to 21, 2015.

Ironwood Pharmaceuticals To Host Third Quarter 2015 Investor Update Call

Ironwood Pharmaceuticals To Host Third Quarter 2015 Investor Update Call

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its third quarter 2015 investor update conference call and webcast at 4:30 p.

Ironwood Reports Positive Top-Line Results From Phase III Trial Of 72 Mcg Linaclotide In Adults With Chronic Idiopathic Constipation

Ironwood Reports Positive Top-Line Results From Phase III Trial Of 72 Mcg Linaclotide In Adults With Chronic Idiopathic Constipation

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that the Phase III clinical trial of its 72 mcg dose of linaclotide in adults with chronic idiopathic constipation (CIC) met the primary endpoint.

Ironwood Pharmaceuticals (IRWD) Flagged As Strong On High Volume

Ironwood Pharmaceuticals (IRWD) Flagged As Strong On High Volume

Trade-Ideas LLC identified Ironwood Pharmaceuticals (IRWD) as a strong on high relative volume candidate

Ironwood Pharmaceuticals To Present At Morgan Stanley Global Healthcare Conference

Ironwood Pharmaceuticals To Present At Morgan Stanley Global Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Morgan Stanley Global Healthcare Conference on Thursday, September 17, 2015 at 12:55 p.

First Week of IRWD October 16th Options Trading

First Week of IRWD October 16th Options Trading

Investors in Ironwood Pharmaceuticals Inc. saw new options become available this week, for the October 16th expiration.

Ironwood Pharmaceuticals Provides Second Quarter 2015 Investor Update

Ironwood Pharmaceuticals Provides Second Quarter 2015 Investor Update

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today provided an update on its second quarter 2015 and recent business activities.

Ironwood And Allergan Enter Agreement To Co-Promote VIBERZI For Irritable Bowel Syndrome With Diarrhea (IBS-D) In The U.S.

Ironwood And Allergan Enter Agreement To Co-Promote VIBERZI For Irritable Bowel Syndrome With Diarrhea (IBS-D) In The U.S.

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today an agreement with Allergan plc for the U.

Ironwood Progresses SGC Stimulator Platform With Positive Top-Line Phase I Data On IW-1973

Ironwood Progresses SGC Stimulator Platform With Positive Top-Line Phase I Data On IW-1973

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced today positive top-line data from a Phase I study of IW-1973, its lead investigational soluble guanylate cyclase (sGC) stimulator.

Ironwood Pharmaceuticals To Host Second Quarter 2015 Investor Update Call

Ironwood Pharmaceuticals To Host Second Quarter 2015 Investor Update Call

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its second quarter 2015 investor update conference call and webcast at 4:30 p.

First Week of IRWD February 2016 Options Trading

First Week of IRWD February 2016 Options Trading

Investors in Ironwood Pharmaceuticals Inc. saw new options begin trading this week, for the February 2016 expiration.

Synergy Rises on Positive Results from Constipation Drug Study

Synergy Rises on Positive Results from Constipation Drug Study

Synergy Pharmaceuticals' experimental drug plecanatide significantly reduced chronic constipation compared to a placebo, achieving the primary goal of a late-stage study.

Synergy A Potential Takeover Target After Constipation Drug Data

Synergy A Potential Takeover Target After Constipation Drug Data

The shares of Synergy Pharmaceuticals are rallying after the company announced that its chronic constipation treatment had met its primary endpoint in a Phase 3 clinical trial.

Ironwood Pharmaceuticals (IRWD): Heavy Pre-Market Activity

Ironwood Pharmaceuticals (IRWD): Heavy Pre-Market Activity

Trade-Ideas LLC identified Ironwood Pharmaceuticals (IRWD) as a pre-market mover with heavy volume candidate

Trade-Ideas: Ironwood Pharmaceuticals (IRWD) Is Today's Pre-Market Mover With Heavy Volume Stock

Trade-Ideas: Ironwood Pharmaceuticals (IRWD) Is Today's Pre-Market Mover With Heavy Volume Stock

Trade-Ideas LLC identified Ironwood Pharmaceuticals (IRWD) as a pre-market mover with heavy volume candidate

Ironwood Pharmaceuticals Prices $300 Million Of Convertible Senior Notes

Ironwood Pharmaceuticals Prices $300 Million Of Convertible Senior Notes

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced the pricing of $300 million aggregate principal amount of convertible senior unsecured notes that will mature on June 15, 2022 (the Notes).

Ironwood Pharmaceuticals Announces Proposed Offering Of $300 Million Of Convertible Senior Notes

Ironwood Pharmaceuticals Announces Proposed Offering Of $300 Million Of Convertible Senior Notes

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that it intends to offer, subject to market and other conditions, $300 million aggregate principal amount of convertible senior unsecured notes that will mature...

Ironwood Pharmaceuticals To Present At Goldman Sachs 36th Annual Global Healthcare Conference

Ironwood Pharmaceuticals To Present At Goldman Sachs 36th Annual Global Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Goldman Sachs 36 th Annual Global Healthcare Conference on Wednesday, June 10, 2015 at 1:20 p.

Today's Weak On High Volume Stock: Ironwood Pharmaceuticals (IRWD)

Today's Weak On High Volume Stock: Ironwood Pharmaceuticals (IRWD)

Trade-Ideas LLC identified Ironwood Pharmaceuticals (IRWD) as a weak on high relative volume candidate

First Week of July 17th Options Trading For Ironwood Pharmaceuticals (IRWD)

First Week of July 17th Options Trading For Ironwood Pharmaceuticals (IRWD)

Investors in Ironwood Pharmaceuticals Inc. saw new options become available this week, for the July 17th expiration.

Ironwood Presents Gastrointestinal Disease Research At Digestive Disease Week® 2015

Ironwood Presents Gastrointestinal Disease Research At Digestive Disease Week® 2015

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that the company and its collaborators will present data from two gastrointestinal disease research programs during Digestive Disease Week ® (DDW)...

Ironwood Pharmaceuticals To Present At Bank Of America Merrill Lynch 2015 Health Care Conference

Ironwood Pharmaceuticals To Present At Bank Of America Merrill Lynch 2015 Health Care Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Bank of America Merrill Lynch 2015 Health Care Conference on Wednesday, May 13, 2015 at 3:40 p.

Ironwood Pharmaceuticals Provides First Quarter 2015 Investor Update

Ironwood Pharmaceuticals Provides First Quarter 2015 Investor Update

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today provided an update on its first quarter 2015 and recent business activities.

TheStreet Quant Rating: D (Sell)